302 related articles for article (PubMed ID: 27342578)
21. Association of FOXE1 polyalanine repeat region with papillary thyroid cancer.
Bullock M; Duncan EL; O'Neill C; Tacon L; Sywak M; Sidhu S; Delbridge L; Learoyd D; Robinson BG; Ludgate M; Clifton-Bligh RJ
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1814-9. PubMed ID: 22736773
[TBL] [Abstract][Full Text] [Related]
22. The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma.
He H; Li W; Liyanarachchi S; Wang Y; Yu L; Genutis LK; Maharry S; Phay JE; Shen R; Brock P; de la Chapelle A
J Clin Endocrinol Metab; 2018 Apr; 103(4):1369-1379. PubMed ID: 29121253
[TBL] [Abstract][Full Text] [Related]
23. Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer.
Tam AA; Özdemir D; Çuhacı N; Başer H; Aydın C; Yazgan AK; Ersoy R; Çakır B
Endocrine; 2016 Sep; 53(3):774-83. PubMed ID: 27090526
[TBL] [Abstract][Full Text] [Related]
24. The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl.
Takahashi M; Saenko VA; Rogounovitch TI; Kawaguchi T; Drozd VM; Takigawa-Imamura H; Akulevich NM; Ratanajaraya C; Mitsutake N; Takamura N; Danilova LI; Lushchik ML; Demidchik YE; Heath S; Yamada R; Lathrop M; Matsuda F; Yamashita S
Hum Mol Genet; 2010 Jun; 19(12):2516-23. PubMed ID: 20350937
[TBL] [Abstract][Full Text] [Related]
25. Selected single-nucleotide polymorphisms in FOXE1, SERPINA5, FTO, EVPL, TICAM1 and SCARB1 are associated with papillary and follicular thyroid cancer risk: replication study in a German population.
Sigurdson AJ; Brenner AV; Roach JA; Goudeva L; Müller JA; Nerlich K; Reiners C; Schwab R; Pfeiffer L; Waldenberger M; Braganza M; Xu L; Sturgis EM; Yeager M; Chanock SJ; Pfeiffer RM; Abend M; Port M
Carcinogenesis; 2016 Jul; 37(7):677-684. PubMed ID: 27207655
[TBL] [Abstract][Full Text] [Related]
26. The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population.
Matsuse M; Takahashi M; Mitsutake N; Nishihara E; Hirokawa M; Kawaguchi T; Rogounovitch T; Saenko V; Bychkov A; Suzuki K; Matsuo K; Tajima K; Miyauchi A; Yamada R; Matsuda F; Yamashita S
J Med Genet; 2011 Sep; 48(9):645-8. PubMed ID: 21730105
[TBL] [Abstract][Full Text] [Related]
27. Expression and clinical significance of FOXE1 in papillary thyroid carcinoma.
Fan Y; Ding Z; Yang Z; Deng X; Kang J; Wu B; Zheng Q
Mol Med Rep; 2013 Jul; 8(1):123-7. PubMed ID: 23715628
[TBL] [Abstract][Full Text] [Related]
28. Missense polymorphisms in XIAP-associated factor-1 (XAF1) and risk of papillary thyroid cancer: correlation with clinicopathological features.
Kim SK; Park HJ; Seok H; Jeon HS; Kim JW; Chung JH; Kwon KH; Woo SH; Lee BW; Baik HH
Anticancer Res; 2013 May; 33(5):2205-10. PubMed ID: 23645777
[TBL] [Abstract][Full Text] [Related]
29. Genotype Analyses in the Japanese and Belarusian Populations Reveal Independent Effects of rs965513 and rs1867277 but Do Not Support the Role of FOXE1 Polyalanine Tract Length in Conferring Risk for Papillary Thyroid Carcinoma.
Nikitski AV; Rogounovitch TI; Bychkov A; Takahashi M; Yoshiura KI; Mitsutake N; Kawaguchi T; Matsuse M; Drozd VM; Demidchik Y; Nishihara E; Hirokawa M; Miyauchi A; Rubanovich AV; Matsuda F; Yamashita S; Saenko VA
Thyroid; 2017 Feb; 27(2):224-235. PubMed ID: 27824288
[TBL] [Abstract][Full Text] [Related]
30. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
31. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
32. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
33. Association between single nucleotide polymorphisms of upstream transcription factor 1 (USF1) and susceptibility to papillary thyroid cancer.
Yuan Q; Bu Q; Li G; Zhang J; Cui T; Zhu R; Mu D
Clin Endocrinol (Oxf); 2016 Apr; 84(4):564-70. PubMed ID: 26052935
[TBL] [Abstract][Full Text] [Related]
34. Common variants at 9q22.33, 14q13.3, and ATM loci, and risk of differentiated thyroid cancer in the French Polynesian population.
Maillard S; Damiola F; Clero E; Pertesi M; Robinot N; Rachédi F; Boissin JL; Sebbag J; Shan L; Bost-Bezeaud F; Petitdidier P; Doyon F; Xhaard C; Rubino C; Blanché H; Drozdovitch V; Lesueur F; de Vathaire F
PLoS One; 2015; 10(4):e0123700. PubMed ID: 25849217
[TBL] [Abstract][Full Text] [Related]
35. 1513A>C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters.
Dardano A; Falzoni S; Caraccio N; Polini A; Tognini S; Solini A; Berti P; Di Virgilio F; Monzani F
J Clin Endocrinol Metab; 2009 Feb; 94(2):695-8. PubMed ID: 19017759
[TBL] [Abstract][Full Text] [Related]
36. Associations between rs965513/rs944289 and papillary thyroid carcinoma risk: a meta-analysis.
Ai L; Liu X; Yao Y; Yu Y; Sun H; Yu Q
Endocrine; 2014 Nov; 47(2):428-34. PubMed ID: 24723258
[TBL] [Abstract][Full Text] [Related]
37. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
39. Association of Polygenic Score With Tumor Molecular Subtypes in Papillary Thyroid Carcinoma.
Wang JR; Zafereo ME; Wang W; Joshu C; Ray D
J Clin Endocrinol Metab; 2023 Dec; 109(1):e306-e313. PubMed ID: 37453101
[TBL] [Abstract][Full Text] [Related]
40. Are the SNPs of NKX2-1 associated with papillary thyroid carcinoma in the Han population of Northern China?
Ai L; Yu Y; Liu X; Wang C; Shi J; Sun H; Yu Q
Front Med; 2014 Mar; 8(1):113-7. PubMed ID: 24452548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
